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Traditional Chinese medicine (TCM) is an important part of primary health care in Asian
countries that has utilized complex herbal formulations (consisting 2 or more medicinal
herbs) for treating diseases over thousands of years. There seems to be a general
assumption that the synergistic therapeutic effects of Chinese herbal medicine (CHM)
derive from the complex interactions between the multiple bioactive components within
the herbs and/or herbal formulations. However, evidence to support these synergistic
effects remains weak and controversial due to several reasons, including the very
complex nature of CHM, misconceptions about synergy and methodological challenges
to study design. In this review, we clarify the definition of synergy, identify common
errors in synergy research and describe current methodological approaches to test for
synergistic interaction. We discuss the strengths and weaknesses of these models in
the context of CHM and summarize the current status of synergy research in CHM.
Despite the availability of some scientific data to support the synergistic effects of
multi-herbal and/or herb-drug combinations, the level of evidence remains low, and the
clinical relevancy of most of these findings is undetermined. There remain significant
challenges in the development of suitable methods for synergistic studies of complex
herbal combinations.
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INTRODUCTION
The “one drug, one target, one disease” approach has for some time remained the conventional
pharmaceutical approach to the development of medicines and treatment strategies. However, over
the last decade, this mono-substance therapy model has gradually shifted toward the adoption of
combination therapies, in which multiple active components are employed. This paradigm shift
has been partly driven by its limited effectiveness in chronic diseases, treatment resistance, and
side effects of synthetic mono-drugs. Recent evidence has demonstrated that combination therapy
could provide greater therapeutic benefits to diseases such as AIDS, cancer, atherosclerosis and
diabetes, all of which possess complex etiology and pathophysiology and therefore are difficult to
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treat using single drug target approach (Devita et al., 1975;
Chesney et al., 2000; Jukema and van der Hoorn, 2004; Weber
and Noels, 2011). Moreover, advances in analytical chemistry and
molecular biology methods have broadened our understanding
of therapeutic targets of diseases and potential multi-target
treatment approaches. Significant progress has been made in
the study of synergistic effects of drugs. For instance, a recent
study has demonstrated the synergistic effect of the combination
of metformin and aspirin in treating pancreatic cancer (Yue
et al., 2014). In parallel, research into synergistic interactions of
multi-component herbal preparations and their interactions with
pharmaceutical drugs has also attracted great interest in recent
years.
Traditional Chinese medicine (TCM) has been used over
thousands of years for the management of disease, maintenance
of health, and prolongation of life expectancy in China and
other Asian countries such as Japan and Korea. Chinese herbal
medicine (CHM) is a key modality of TCM, in which up to 20
herbs are used in combination in a complex herbal formulation.
Substantial progress has been made over the last decades in the
study of efficacy and mode of actions of some commonly used
herbs and formulations (Lam et al., 2006; Kong et al., 2009).
However, evidence to support synergistic effects of multiple herbs
and their active components remains controversial. For example,
some studies have suggested that meaningful synergistic and
therapeutic effects of herbal formulations were unlikely due to
the low/extremely low levels of active components existed in
the herbs (Williamson, 2001; Danz et al., 2002). This has led
to skepticism that herbal therapies are merely placebo effects
(Tausk, 1998). In contrast, numerous studies have demonstrated
that herbal extracts as a whole and/or multiple herbs in complex
formulations offer better efficacies than equivalent doses of
individual active ingredients and/or herbs when used alone,
highlighting the significance of synergistic action in herbal
therapies (Leonard et al., 2002; Scholey and Kennedy, 2002;
Zhang et al., 2014). In this article, we aim to present a
comprehensive review of the current status of research on the
synergistic effects of CHM and how they are effectively measured.
DEFINITION OF SYNERGY
Generally, synergy is defined as the interaction of two or more
agents to produce a combined effect greater than the sum
of their individual effects (van Vuuren and Viljoen, 2011). In
medicinal research field, however, the understanding of synergy
is complicated. Spinella (2002) has classified the concept of
synergy broadly into two main categories based on the mode
of actions—pharmacodynamic and pharmacokinetic synergy
(Spinella, 2002). The first type of synergy describes two or
more agents that work on the same receptors or biological
targets that result in enhanced therapeutic outcomes through
their positive interactions. The second type of synergy results
from interactions between two or more agents during their
pharmacokinetic processes (absorption, distribution, metabolism
and elimination) leading to changes of the agents quantitatively
in the body and hence their therapeutic effects (Spinella, 2002).
The concept of synergy is an intrinsic part of TCM philosophy
and is often described in a more holistic way. The complex
synergistic interactions among the herbs in complex CHM
formulations (Fufang) are believed to be able to enhance
the bioavailability of active components, promote therapeutic
effects, and/or reduce toxicity (Jia et al., 2004). The design
of herbal formulations follows the principle of compatibility,
called “Peiwu,” which requires the considerations of different
interrelationships of herbal ingredients including synergism
(Xiang Xu), assisting (Xiang Shi), detoxication (Xiang Sha and
Xiang Wei), antagonism (Xiang Wu), and rejection (Xiang
Fan) (Jia et al., 2004). Based on this principle, different herbs
are combined following “Jun-Chen-Zuo-Shi” (also known as
“Emperor–Minister-Assistant-Courier”) rule to achieve desirable
effects and/or tominimize side-effects. “Jun” is the main herb in a
herbal formula with a relatively higher ratio directly targeting the
disease; “Chen” is an adjuvant herb to promote therapeutic effect
of the key herb or to target the accompanying symptoms; “Zuo”
is usually used for reducing the side-effects of the herbal formula;
“Shi” is the herb that guides the active ingredients to reach the
target organs or to harmonize their actions.
It is important not to confuse synergistic effect with additive
effect. Synergy occurs when two or more drugs/compounds are
combined to produce a total effect that is greater than the sum
of the individual agents (Chou, 2010; Breitinger, 2012), while
an additive effect is an add up of individual effects where each
individual agent is not affecting the other (no interactions). The
concept that the additive effect of two drugs is their “arithmetic
sum” is a misconception. The additive effect is not simply the
sum of the effects of A plus B. For instance, if agents A and B
exert an inhibitory effect as 60 and 70% at certain dosage level,
respectively, it is incorrect to state their additive effect is 130% at
this dosage. The additive effect needs to be determined using a
more complex mathematical algorithm equation.
Comparing combination activity to individual activity at the
same dosage or effect level is a common error in synergy studies.
A large amount of papers were found to report synergistic
effect when the ED50 value of a combination was significantly
lower than that of each individual component with a P < 0.05.
This approach seems logical, but it actually cannot distinguish
between an additive effect and a synergistic effect as it is still the
comparison between combination and individual effects. Similar
errors are very common in animal and clinical trials where it
is difficult to apply rigorous synergy determining methods due
to practical reasons (e.g., costs, curation of the study, ethical
issues, etc). In these studies, researchers estimated synergism
by simply comparing the effect of the combination with that
of individual components, which unfortunately would lead to
a wrong conclusion. Thus, more efficient and practical models
need to be developed to determine synergistic effects of multi-
component preparations in animal and human studies.
METHODS TO QUANTIFY SYNERGY
Currently, no unified methodology is available for synergy
research to facilitate the different understandings of the mode
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of action of synergy; this has led to the question that whether
the drug interactions observed are genuine synergistic effects
(Chou, 2010). However, several methodological approaches have
been developed and are used for combinational drug therapies.
Loewe additivity and Bliss independent are the two oldest
and major reference classes for synergy studies in the last few
decades (Tang et al., 2015). Loewe additivity is usually applied
for the case where the drugs have similar modes of action
on the same target or pathway (pharmacokinetic) (Tang et al.,
2015). In contrast, the Bliss independence model is expected to
hold truth for non-interacting drugs that elicit their responses
independently (pharmacodynamic) (Tang et al., 2015). In recent
years, many other methods based on these two models have
been developed and adapted for the study of synergistic effects
of multi-component preparations. Some of the most popular
models including the combination index and isobole method
(both derived from Loewe additivity), systems biology analysis
(used for multi-target synergy), and several specific assays for
synergistic studies of antimicrobial agents are discussed here. The
strengths and limitations of these methods are summarized in
Table 1.
Combination Index
Recently it has been demonstrated that synergy follows
physicochemical mass-action law, which briefly states that the
ratio between the concentration of reactants and products is
constant for a chemical reaction mixture that is in equilibrium.
From mass-action law, a simplified mathematic equation for
the combination index (CI) was further developed for the
quantitative determination of synergy in multiple agents acting
on the same target/receptor (Chou, 2010). Synergism occurs
when the CI value is< 1 (the more the CI value approaches 0, the
stronger the synergistic effect); additive effect occurs when the CI
value is equals to 1, and antagonism happens when the CI value
is >1.
The CI is a practical model used for the analysis of synergy of
a multi-component combination in a fixed ratio. To calculate the
CI, the dose-response curves (inhibitory effect, stimulatory effect,
etc.) of individual components A and B and their combination
in a fixed ratio are determined using the same assay. The
doses of each individual component that achieves a specified
effect (e.g. 50%, ED50) are determined. Further, the doses of
A and B required in the combination to produce the same
level of effect can be calculated. Then, based on the doses,
the synergism/addition/antagonism is calculated according to
Equation (1) below for two agents and Equation (2) for multiple
agents.
In addition, computer software including “CalcuSyn” and
its third-generation “CompuSyn” have been developed, which
greatly facilitates the CI analysis (Patrick Reynolds and Maurer,
2005; Chou, 2006). By inputting the dose-effect data of agents
1 and 2 and their combination, the software can generate
a Fa (effect level)–CI curve, which demonstrates a complete
dataset of CI values (represent antagonistic/additive/synergistic
interactions) at all tested doses. Also, a CI-Fa (effect levels)
can be generated (an example is shown in Figure 1). This
model can also be applied for the determination of interactions
among multiple agents in a mixture. The calculation is based
on Equation (2), which demonstrates n-drug combination at
x% inhibition. Examples using CI model for the determination
of synergistic interaction in CHM are discussed in Section
Synergistic Interactions within Single Herb Analyzed by CI or
Isobologram Method.
CI =
D1
d1
+
D2
d2
(1)
n(CI)x =
∑n
j= 1
(D) j(
d
)
j
(2)
n(CI)x = combination index for n drugs at x% inhibition
D1 and D2 = doses of individual constituent alone, required to
produce a chosen effect level (usually ED50)
d1 to d2= the doses of individual constituent in the combination
required to produce the same effect, respectively.
It is worth mentioning that many studies also reported a
synergistic effect when certain pharmacological effects can be
observed with a drug combination, but not with one or more of
its individual components. This effect is classified as potentiation
or augmentation rather than synergism based on Chou’s theory
(Chou, 2010). If an individual component does not generate
an effect when used alone, the D1 value is equals to 0, thus
the synergy cannot be determined in the CI equations. This
potentiation or augmentation effect can be considered as a form
of complementary interactions.
Isobole Method
Isobologram, was first introduced by Fraser in 1870 based
on Loewe additivity (Fraser, 1872). This method has been
widely accepted as one of the most practical models in
terms of experimental design and effectiveness to illustrate the
synergistic/additive/antagonistic interactions. Similar to the CI
model, the isobole method requires the determination of dose-
response relationship of the combination and its individual
components independently to assess if synergism exists. This
is expressed as a dose response curve on an isobole graph
as shown in Figure 2. The isobole is an “iso-effect” curve, in
which a combination of components (A or B) at different dose
levels is represented on the graph, the axes of which are the
dose-axes of the individual constituent (A and B). The dashed
line joining the points (i.e. ED50 of A and B) which represent
the same dosage required from the combination as the sum
of the individual component to reach the same effect. If the
dots of the combination falls on this dashed line, it represents
an additive effect, i.e., no interactions between components A
and B. If synergy occurs the curve becomes “concave.” The
opposite applies for antagonism representing by a “convex”
isobole (Figure 2). It is also possible to have synergy at one
dose combination and antagonism at another, with the same
substances and this would give a complicated isobole with a
wave-like or even elliptical appearance.
In theory, isobologram and Fa-CI plot are both based on
the same CI equation and therefore should yield an identical
conclusion. However, isobologram explains synergy from a
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TABLE 1 | Comparison of current models of synergy methods.
General
methods
Brief description Strengths Limitations
Combination
index
A scientific term to quantitatively depict
synergism (CI < 1), additive effect (CI = 1), and
antagonism (CI > 1).
1) One of the most practical methods
experimentally.
2) The most demonstrative method for the
proof of synergy effects.
3) No limitation for the number of ingredients in
the tested combination.
1) Must be able to determine dose-response of
individual constituents and combination.
Isobole
method
A graphical procedure that can either represent
additive, synergistic, or antagonistic
interactions, depending on the position of thc
dose of combination to the “iso-effect” linear
line.
1) The oldest and well-established method.
2) One of the most practical experimentally.
1) Must be able to determine dose-response of
individual constituents and combination.
2) Generally, only applicable for two drug
combination.
Systems
biology
A computational and mathematical modeling
for predicting and understanding the network
of components and protein/gene targtes
binding biological system.
1) Suitable for study of synergy of
multi-components, prodrugs, and novel
targets.
2) Being able to investigate the mechanisms of
action of a combination, and identify the key
active components.
1) Large data sets including chemical,
chemogenomics, pharmacological data
and the compounds’ potential targets
information are required.
Methods
specific in
Brief description Strengths Limitations
microbiology
Diffusion
assays
Positive/negative interactions in the mixture are
observed via comparing the bacteria growing
inhibition zone diffused in the agar with that of
individual agent.
1) Impact on microorganism can be
investigated in vitro.
2) Simply, visual, qualitative representation of
synergistic (or antagonistic) effect of
individual components used together.
1) These assays are subject to many variables
which may influence the results and should at
the most be used as a qualitative guide only.
2) Cannot differentiate synergism from additive
effect.
Checkerboard
array
The combination of two agents is contructed
on a in two dimension array, and the
positive/negative interactions are determined
by comparing the combinational and individual
inhibitory activity which can be quantified by
fractional inhibitory concentration (FIC).
1) Clear visualization on a single plate of
contribution of the individual components.
2) Can test multiple concentrations
simultaneously.
3) Easy to carry out and interpret
1) Assessment of viability is not always accurate
when replying on turbidometric readings.
2) Laborious for combination of three, not
feasible for combinations of four or more.
3) Rely on a linear dose-response curve for all
components.
4) All plants in the combination tested required
to be at equal ratios.
Time-kill
assay
Positive/negative interactions among
multi-components in the mixture are
determined via comparing individual and
combinational bacteri cidal activity over a series
of time intervals.
1) One of the best methods to study synergy
of antimicrobial agents.
2) The bacterial cidal effect is monitored over
time which is not possible with the
frequently used MIC assays.
1) The method is labor intensive and requires
a number of steps where variables may be
introduced.
2) Difficult in interpretation of results because
relatively few antibiotic concentrations are
examined.
3) Rely on the reading at one time point
(usually 24 h) as the sole determinant of the
interaction.
dose-oriented perspective (reaching the same therapeutic activity
but with a lower dose level required), while Fa-CI plot from
an effect-oriented perspective (resulting in a higher therapeutic
activity at the same dosage level). Additionally, Fa-CI plot can
be used to determine multi-component interactions, whereas
isobologram is only feasible for a two drug combination as it is
not possible to construct multidimensional isobologram curves.
Both CI and isobologram models are designed for evaluating
the synergistic/antagonistic interaction between two or more
single-entity agents acting on the same target/receptor.
Even though these models have been recently used for
analyzing possible synergistic interactions in simple herbal
formula (herb-pair), they are by and large less adequate
for evaluation of the complex interactions among multiple
bioactive components of CHM formulations (Gu and
Chen, 2014) (for more detailed discussions see Section
Current Status of Synergy Research in Chinese Herbal
Medicine).
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FIGURE 1 | An example of utilizing CI model to determine synergy for the combination of agent AB in certain fixed ratio. (A) Dose-effect curves for A, B,
and AB, respectively. (B) CI value-Fa (Fa: fraction affected level) curve for AB generated from CalcuSyn based on the dose-response curves shown in (A). It
demonstrated that synergistic effect is starting from 60% effective level (Fa = 0.6) and this synergistic effect continues to increase (CI < 1) at higher effect levels in AB.
Systematic Analysis/System to System
(S2S)
The CI and isobologram methods both require combination-
by-combination evaluations of individual components in a
mixture specifically acting on the same target/receptor. However,
for a complex combinational therapy especially TCM multi-
herb formulations, which often contain hundreds of potentially
bioactive components that may act on a network targets, it is
technically impossible to use these two models to evaluate all
combinations of bioactive components on each of the target one
by one.
A systematic analysis (or S2S) approach integrating literature,
experimental data, and computational sciences has been recently
developed to address the multi-target synergistic actions. To
conduct this analysis, the three-dimensional structures of
individual compounds in the combination are obtained from
relevant database, handbooks or literature, and the known
crystal structures of all the key genes/proteins associated with
targeted disease are retrieved from relevant data banks or
databases. The network constructions between agents and
targeted protein/genes are then constructed via a molecular
docking approach. Molecular docking is usually applied for
computer-assisted drug design, which predicts the predominant
binding mode(s) of a ligand with a protein of known structure.
Here, it is used to analyse binding modes between the potential
active compounds and their corresponding target proteins based
on their structure binding modes, in order to generate a drug-
target network. The predicted interaction between bioactive and
targeted receptors from the generated network can either be
confirmed by literature or validated through experimental studies
(Wang X. et al., 2012; Leung et al., 2013). This model investigates
the multi-target mechanisms of action of multi-constituents
mixtures and identifies the key active components, which can
bind to most of the corresponding targets. In addition, this
method can be used in drug development through selecting and
combining the most active components that act on the maximum
amount of the protein or gene targets. This minimal effective
composition with definite constituents and controllable quality
can optimize the composition of the mixture while maintaining
their curative effects (Li et al., 2012; Liang et al., 2012).
The S2S approach has gained popularity as a promising and
valuable tool to evaluate synergy of complex herbal formulations
(Lee, 2015). However, due to the poor understanding of
the chemical and pharmacological properties of bioactive
constituents of many TCM herbs, the application of this method
in studying synergistic effects of TCM herbs to gain insight of the
holistic approach of CHM remains a challenge (Wang X. et al.,
2012).
Models Used in Microbiology Studies
In microbiology, several bioassays and mathematics models
have been developed and applied to the investigations of
the synergistic anti-bacterial effects of individual bioactive
components of Chinese herbs and antibiotic agents including
diffusion assay, checkerboard array, and time-kill assay.
Diffusion Assay
This is a simple, visual and qualitative microbiology assay that
can be used to investigate the combinational effect of individual
components used together. Inhibition/kill studies in agar or
broth, microscopy and molecular analysis are used to investigate
the mode of action of antimicrobial agents. In this method,
each individual test samples (A or B) and their combination
(A+B) are placed in separate wells or disc on agar containing
pathogenic organisms, and their inhibition zones are compared.
If the inhibition zone of the combination is larger than that from
A or B, positive interactions are noted. Should the inhibition
zone of the combination be smaller than A or B independently,
then negative interactions are noted. Since it only compares the
inhibition zone of combination with individual component, it
cannot differentiate synergism from additive effect. Moreover,
this method is subject to many variables which may influence the
results and is used as a qualitative guide only.
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FIGURE 2 | The lsobole method for synergy study. Dose A and Dose B are the individual concentrations of Components A and B; Dose AB are the
concentrations of A and B in the combination. The dashed line shows zero interaction between A and B, which represents a simple additive effect. The effect of the
combination equals the sum of the effects from individual components. (A) Effect of synergy: the dot is underneath the dashed line. (B) Effect of antagonism: The dot
is above the dashed line; Addition: The dot is on the dashed line.
Checkerboard Array
This method is used for evaluating synergistic interactions of
antimicrobial agents against bacteria or fungi. In this method,
the effects of interactions are assessed through the serial dilution
of two agents A and B [two-fold dilution to four times of
estimatedminimum inhibitory concentration (MIC); Hsieh et al.,
1993). A checkerboard is constructed in a two dimension array
with the same amount of series dilutions of agent A and
agent B in x and y-axis. Thus, each tube/well in the middle
of checkerboard contains a unique combination of agent A
and B being tested. With the addition of cell viability dyes
such as resazurin or MTT, the inhibitory activity of individual,
and the combination of components can be visually assessed
and quantified by fractional inhibitory concentration (FIC). In
addition, the turbidity of the wells prior to and after incubation
with the microbe can be assessed for their difference, which can
then also be used as an indicator of MIC. This method is easy
to carry out and interpret the interactions between two agents,
andmulti-concentrations can be tested simultaneously. However,
factors such as compound/herb solubility in the wells, biofilm
formation, and interactions between the compounds/herbs with
the indicator dyes, all of which can be problematic for the
turbidometric and/or colorimetric readings, can result in the
inaccurate assessment of viability of the test microbe.
Time-Kill Assay
This method provides descriptive information on the
relationship between bactericidal activity and the concentration
of a test substance. The principle involves exposing the inhibitor
to a selected pathogen and, at selected time intervals, aliquots
are sampled and serially diluted. The dilutions are plated out,
incubated at optimum conditions for the test organism, and
the colony for forming units (CFU) are counted and plotted
logarithmically against time. Depending on the curve of the dose
response, either an additive, synergistic, or antagonistic effects
is determined. Since this method can monitor the bactericidal
effect over different time-points, it is quite labor intensive and
requires a number of steps where variables may be introduced.
It is difficult to interpret results because relatively few antibiotic
concentrations are examined.
CURRENT STATUS OF SYNERGY
RESEARCH IN CHINESE HERBAL
MEDICINE
For the last decades, it is well-accepted that combined drug
therapies may provide better clinical outcomes in the treatment
of some conditions such as hypertension, cancer, depression and
HIV infection. Synthetic pharmaceutical drugs are usually single
chemical entities acting on a single biological target. Combined
drug therapies are formulated in a fashion to augment the
total effects in treating the target condition, reduce the side
effect via dose-sparing of the active components, or address
different metabolic interdependence, mediators or risk factors
of diseases through a variation of independent biomolecular
targets. However, due to the limitation of the methodology
currently available, it is still challenging to identify the best
possible combinations from the large amount of the existing
drugs, evaluate their molecular interactions, and establish their
efficacy and safety (Orloff, 2005).
In contrast to western style combined drug therapies where
chemical properties and pharmacological effects of individual
compounds are well-defined, Chinese herbal formulations are
constructed according to TCM theories (“Peiwu” and “Jun-
Chen-Zuo-Shi”). Despite the long history of clinical use and
a solid theoretical basis, the multi-component and multi-target
nature of CHM poses a huge challenge to the study of the
mechanisms of action, including synergistic effects underpinning
the complex herbal formulations (Wang et al., 2009). With the
advance in mathematic modeling (e.g., CI, isobologram) and
computer technology (e.g., systems biology analysis), there has
been a growing number of systemic and mechanistic studies over
the past two decades aiming to provide better scientific evidence
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and understanding of synergistic effects of Chinese herbal
formulation. In this study, we conducted a thorough literature
search (keywords used: “Synergism” or “Synergy” or “Synergistic”
and “Chinese herbal medicine” or “Chinese medicinal herbs”) in
PubMed and Google scholar from the period of 1990 to 2015.
The numbers of studies using proper synergy models are shown
in Figure 3. Key studies identified are summarized in Table 2.
Synergy Reflected in Chemical Fingerprint
Chemical fingerprint studies utilizing high-performance
liquid chromatography chromatography, gas chromatography,
liquid chromatography–mass spectrometry and chemometric
resolution methods have been conducted to detect changes in the
amount of pharmacologically active compounds in individual
herbs when given in combination (Han et al., 2007; Wang et al.,
2011; Kaliappan et al., 2014). During the decocting preparation,
the chemical composition is often altered due to solvent’s
polarity, heating effects or changed pH environment (Li, 2014).
These changes in chemical composition could account for the
increased therapeutic effects and/or reduced side effects of the
individual herbs. Li et al. (2006) demonstrated that the amount of
main volatile chemical components present in Rhizoma Ligustici
Chuanxiong (Chuanxiong) and Radix Paeoniae Rubra (Chishao),
which are commonly used to promote blood circulation and
remove stasis, were markedly altered when given together due
to the formation of non-volatile, water soluble salts during the
decoction process (Li et al., 2006). In addition, the amount of
aconitine, a toxic component of Aconitum carmichaeli Debx.
(Fuzi) is significantly reduced due to its chemical reaction with
tannine under high temperature.
Chemical fingerprint studies have also shown that new
compounds are formed when herbs are given in combination
during the preparation. For instance, Wang Y. L. et al. (2012)
identified four new compounds in a Radix Polygalae (Yuanzhi)
and Acorus Tatarinowii Rhizoma (Shichangpu) combination that
were not detected in the individual extracts (Wang Y. L. et al.,
2012). Although, the biological effects of these new compounds
were not evaluated in this study, it provides possible explanations
for the changes in pharmacological properties when herbs are
used in combination.
Synergistic Interactions within Single Herb
Analyzed by CI or Isobologram Method
Individual herbal extracts consist of a complex mixture of
bioactive compounds, concomitant agents and other minor
substances among which interactions can occur leading to
synergistic effects. For example, Ginkgo biloba extract has been
shown to possess an anti-platelet aggregation property (Dutta
Roy et al., 1999), which could contribute to its therapeutic effects
for vascular cognitive impairment through enhancing cerebral
blood flow (Zhang and Xue, 2012). Synergistic interaction
between ginkgolides A and B, two bioactive components of
Ginkgo biloba, has been demonstrated in a platelet aggregation
test using the isobole method (Williamson, 2001).
In a study conducted by Lin et al. (2007), the anti-cancer
property of four H2O sub-fraction phytocompounds (indole-
3-caroxyaldehyde, wedelolactone, luteolin, and apigenin) from
Wedlia chinensis were evaluated using three different androgen
receptor (AR)-dependent cancer cell lines (human PCa22
Rv1, 103E, and LNCaP cells) (Lin et al., 2007). Interestingly,
as revealed by the CI analysis using CalcuSyn software, a
significantly stronger anti-cancer effect was observed when
the four compounds were combined at the same ratio as in
the original herb extract when compared with that of each
individual compound highlighting the synergistic property of
these compounds present in Wedlia chinensis. It is worth
mentioning that the anti-cancer activity was significantly reduced
when any one of these bioactive compounds was removed from
the combination, indicating the significance of the four bioactive
compounds acting as a whole.
Kan et al. (2008) demonstrated the anti-cancer activities of
the three major phthalides mixture [butylidenephthalide (BLP),
senkyunolide A (SKA), and z-ligustilide (LGT)] from Angelica
sinensis with the same ratio as they were in the extract on
colon cancer HT-29 cell line. Although three phthalides mixture
demonstrated synergistic cytoxic effects, it was shown that the
anti-proliferative effects of the whole A. sinensis extract was still
significantly higher than of the corresponding phthalide mixture.
Therefore, it suggested positive interactions of active components
and other co-existing components within the herb (Kan et al.,
2008).
Synergistic Interactions within
Multi-Herbal Combinations
Synergistic Interactions in Herb-Pair Analyzed by CI
or Isobologram Method
Multiple herbs are commonly used in Chinese herbal
formulations, and pose further methodological challenges
in synergy research. Salvia miltiorrhiza (Danshen) and Pueraria
lobate (Gegen) are commonly used in combination for the
treatment of coronary heart disease (Sieveking et al., 2005;
Koon et al., 2011; Ng et al., 2011). A study conducted by
Cheung et al. (2012) demonstrated that the anti-atherogenic
effects of Danshen-Gegen combination in a 7:3 (w/w) ratio
produced synergistic, additive and antagonistic effects in
anti-inflammation, anti-foam cell formation, and anti-vSMC
proliferation, respectively. This was the first study demonstrating
the feasibility of applying CI analysis in the synergy study of
herbal combinations (Wing Shing Cheung et al., 2012).
Several other studies have been conducted to investigate
synergistic interactions of two-by-two combinations in complex
formulations. For example, synergistic effects of five commonly
used medicinal herbs extracts—thyme (Thymus vulgaris),
rosemary (Rosmarinus officinalis), sage (Salvia officinalis),
spearmint (Mentha spicata) and peppermint (Mentha piperita)
were tested in an in vitro study (Yi and Wetzstein, 2011).
In this study, individual extracts were paired at 1:1 ratio and
their anti-cancer activities were compared in SW-479 colon
cancer cell line using CI model by CalcuSyn software. The sage
and peppermint combination (1:1) produced the strongest and
synergistic inhibitory effects on cancer cell growth at the doses
ranging from 31.25 to 125 µg/mL when compared to that of
individual single extracts and other combinations (CI value of
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TABLE 2 | A summary of in vivo and in vitro studies on Chinese herbal extracts or active ingredients that have been reported to produce synergistic
effects on various biology activities.
Method of
synergy
determination
Study
type
Interacting components Therapeutic
activity
Evidence of synergy References
Combination
index
In vitro Escin and cisplatin Anti-cancer Escin (10 and 15µM) combined with cisplatin (3µM)
resulted in a significant synergistic (CI = 0.256 and
0.186) cytotoxic effect in Panc-1 cells.
Rimmon et al.,
2013
In vitro Astragalus membranaceus and
Paeonia lactiflora
Anti-cancer Seven substances were identified from active fraction
combination which represents the synergistic effect for
two herb combination on anti-oxidant activity.
Xu et al., 2014
In vitro Camptotheca acuminate and its
component camptothecin plus
cisplatin
Anti-cancer Both Camptotheca acuminate extract (0.01 to 5 mg/mL)
and its isolated compound camptothecin (0.05 to 1µM)
demonstrated a synergistic effect (CI < 1) in the HEC-1A
and HEC-1B cells when combined with cisplatin
(1–50µM).
Lin et al., 2014
in vivo Polyphyllin I (a steroidal saponin
extracted from Rhizoma of Paris
polyphyllin) and evodiamine (a kind
of alkaloid from Evodia rutaecarpa)
Anti-cancer Combination of Polyphyllin I (200µg/mL) and
platinum (20µg/mL), evodiamine (200µg/mL) and
platinum (20µg/mL), evodiamine (20µg/mL), and
5-FU (300µg/ml) had higher inhibition rates than any
single drug of them (CI <1).
Yue et al., 2013
In vitro Astragalus membranaceus and
Cimicifuga foetida
Anti-cancer The combination of isoferulic acid and calycosin (isolated
from each herb) at a dose ratio of 1:1 resulted in
significant synergy (CI50 = 0.77) in scavenging DPPH
radicals and ferric reducing antioxidant power (FRAP)
assay. This combination also exhibited synergistic effect
at a dose of 1:1 (CI = 0.442) and 2:1 (CI = 0.636) in
HepG2 cell-based assay.
Wang et al.,
2014
In vitro Four anti-proliferative
phytocompounds in Wedelia
chinensis
Anti-cancer Four bioactive compounds were identified in W.
chinensis to inhibit androgen receptor activity in prostate
cancer cells and the four active compounds acting
together exerted strong synergism (CI = 0.39–0.78).
Lin et al., 2007
In vitro Mentha piperita L. and Salvia
officinalis L.
Anti-cancer At 31.25, 62.5, and 125µg/mL dosage levels, cancer
cells treated with Mentha piperita L. plus Salvia officinalis
L. combinations (1:1) showed significantly lower viability
than calculated values based on individual extracts [CI =
0.67 ± 0.09 (<1)].
Yi and
Wetzstein, 2011
In vitro Xanthorrhizol (isolated from
curcuma xanthorrhizza) and
curcumin (not stated for the
source)
Anti-cancer Synergistic activity (CI < 1) was commenced from the
combination xanthorrhizol-curcumin 3:7 to 1:9 to induce
MDA-MB-231 cells death.
Cheah et al.,
2009
In vitro Scutellaria baicalensis, Rabdosia
rubescens, Panax-pseudo
ginseng, Dendranthema
morifolium, and Glycyrrhiza
uralensis, and Serenoarepens
Anti-cancer S. baicalensis and D. morifolium when combined
(equipotent quantities and at 1/2 and 1/4 fractions of
their IC50 value) were additive with a trend toward
synergy, whereas D. morifolium and R. rubescens
together were additive. The remaining two-extract
combinations showed antagonism. The four extracts
together were significantly more effective than the
two-by-two combinations and the individual extracts
alone.
Adams et al.,
2006
in vivo/
in vitro
Realgar-Indigo naturalis formula
(RIF): tetraarsenic tetrasulfide (from
realgar), indirubin (from Indigo
naturalis), and tanshinone IIA (from
Salvia miltiorrhiza)
Anti-cancer Tetraarsenic tetrasulfide, indirubin and tanshinone IIA at
concentrations ranging from 0.25 to 1µM had CI values
<1, indicating synergic effects on human APL cell
differentiation.
Wang L. et al.,
2008
In vitro “Chong Lou Fu Fang”
(CLFF)–Rhizoma Paridis, Fructus
Forsythiae, and Radix Codonopsis
plus 5-fluorouracil (5-FU)
(chemotherapeutic agents)
Anti-cancer The synergistic analysis indicated that CLFF (0.05–0.35
mg/mL) with 5-FU (0.75–75.25µM) had a synergistic
cytotoxicity effect in a relative broad dose inhibition range
(20–95% fraction affected in SGC-7901 cell lines and
5–65% fraction affected in BGC-823 cell lines), while the
synergistic interaction between CLFF and oxaliplatin or
docetaxel only existed in a low dose inhibition range
(≤50% fraction affected in both cell lines).
Liu et al., 2011
(Continued)
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TABLE 2 | Continued
Method of
synergy
determination
Study
type
Interacting components Therapeutic
activity
Evidence of synergy References
Interaction
index
In vitro ASHMI formula and its
components: aqueous extracts of
Lingzhi (Ganoderma lucidum),
Kushen (Sophora flavescens), and
Gancao (Glycyrrhiza uralensis)
Anti-asthma By comparing the interaction index values, constituents
in ASHMI (individual extracts in the percentages of 35,
45, and 20 of Lingzhi, Kushen and Gancao)
synergistically inhibited eotaxin-1 production as well as
Th2 cytokine production.
Jayaprakasam
et al., 2013
Median –effect
analysis/
Combination
index
In vitro Three main phthalides from
Angelica sinensis:
n-butylidenephthalide (BLP),
senkyunolide A (SKA) and
z-ligustilide (LGT)
Anti-cancer Three main Angelica sinensis phthalides (the composition
ratios identical to that in the extracts of Angelica sinensis
and Ligusticum chuanxiong, respectively) in Angelica
sinensis extract yielded a synergistic effect (CI < 1)
whereas Ligusticum chuanxiong extract exerted an
antagonistic effect (CI > 1) on the inhibition of cell
proliferation in colon cancer cells at the tested doses.
Kan et al., 2008
Combination
index and
isobologram
In vitro Strobilanthes crispus (SCS) and
tamoxifen
Anti-cancer The combined SCS (8.5µg/ml or 10.0µg/ml) and
tamoxifen (2.5 to 15µM) treatment displayed strong
synergistic inhibition in MCF-7 (CI = 0.32–0.40) and
MDA-MB-231 (CI = 0.29–0.52) cell growth at low doses
of the antiestrogen.
Yaacob et al.,
2014
In vitro Rhizoma Corydalis and Rhizoma
Curcumae
Anti-cancer A combination of two herbal extracts exhibits the
strongest anticancer cell proliferation effect at the ratio of
3:2 (ezhu to yanhusuo)
Gao et al., 2009
Isobologram In vitro Curcumin (extracted from the
rhizomes of Curcuma species) and
NVP-BEZ235
Anti-cancer Combined treatment of NVP-BEZ235 (0.5–4mM) and
curcumin (30µM) demonstrated synergistic effects on
apoptosis in human renal carcinoma Caki cells.
Seo et al., 2014
In vitro Berberine (from Coptis chinensis
Franch.) and evodiamine (from
Evodiae Fructus)
Anti-cancer Berberine (0–0.1µM) and evodiamine (0–0.18µM)
mixture showed the highest inhibition effect (50.00%) as
compared with berberine and evodiamine used
individually (20.24 and 16.33%, respectively) to induce
apoptosis on human hepatocellular carcinoma
SMMC-7721 cells over 48 h.
Wang X. N.
et al., 2008
“System to
system” (S2S)
mode/System
biology
In vitro/
In vivo
Panax ginseng and Salvia
miltiorrhiza
Myocardial
ischemia
An optimized minimal phytochemical composition (new
formula NSLF6) were achieved from Pananx
ginseng-Salvia miltiorrhiza combination which has activity
for treatment MI through synergistic therapeutic
efficacies between total ginsenosides and total
salvianolic acids via promoting cardiac cell regeneration
and myocardial angiogenesis, antagonistic myocardial
cell oxidative damage.
Liang et al.,
2012
In vivo/
In vitro
Compound Danshen formula
(Salvia Miltiorrhiza, Panax
Notoginseng and Borneol)
Cardiovascular
diseases
Radix Salviae Miltiorrhizae (Danshen) tackled 39 out of
total 41 validated CVD targets (except eNOS and ACE2)
which acted as the emperor (key herb) in this formula,
whereas Panax Notoginseng interacted with 36 potential
targets in which 34 overlapped with Danshen’s targets
and serve as minister and courier drugs.
Li et al., 2012
In vivo/
In vitro
Radix Astragali Mongolici, Radix
Puerariae Lobatae, Radix
Ophiopogonis Japonici, and Radix
Salviae Miltiorrhiza
Cardiovascular
diseases
The structural properties of molecules in four herbs have
substantial differences, and each herb can interact with
significant target proteins related to CVD. Moreover, the
bioactive ingredients from different herbs potentially act
on the same molecular target (multiple-drug-one-target)
and/or the functionally diverse targets but with potentially
clinically relevant associations This study has
demonstrated that multiple-drug-multiple-target-one
-disease therapeutic pattern of TCM formula.
Wang X. et al.,
2012
In vivo Panax ginseng (PG) and Salvia
miltiorrhiza (SM)
Myocardial
ischemia
SLF (SM: PG = 3:7) exerted synergistic therapeutic
efficacies to exhibit better effect on MI compared to PG
or SM.
Liang et al.,
2011
(Continued)
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TABLE 2 | Continued
Method of
synergy
determination
Study
type
Interacting components Therapeutic
activity
Evidence of synergy References
In vivo/
In vitro
Radix curcumae formula: Radix
Curcumae, Fructus Gardeniae,
Moschus, and Borneolum
Cardiovascular
diseases
The pharmacological system generated 58 bioactive
ingredients from the Chinese herbal Radix Curcumae
formula, and predicted 32 potential targets related to the
CCVD. The results indicates that Radix Curcumae share
the most common targets with Fructus Gardeniae (15),
while less common targets with Moschus and
Borneolum (8 and 1, respectively). Further integrated
network shows that Radix Curcumae represents the
principal component for the prevention of CCVD, and
other three medicines serve as adjuvant ones to assist
the effects of the principal component, which together
probably display synergistic actions.
Tao et al., 2013
In vivo Yinchenhao decoction: Artemisia
annua L. Gardenia jasminoids Ellis,
and Rheum Palmatum L.
Hepatic injury
syndrome (HI)
Three major active compounds combination DGR
[6,7-dimethylesculetin (D), geniposide (G), and rhein (R)]
from Yinchenhao decoction, exerts a more robust
therapeutic effect than any one or two of the three
individual compounds by hitting multiple targets in a rat
model of hepatic injury.
Wang et al.,
2013
In vivo Yin-Chen-Hao-Tang (YCHT):
Artemisia annua L. (the monarch
herb), Gardenia jasminoides Ellis
(the minister herb), and Rheum
Palmatum L. (the assistant and
servant herb): 6,7-Dimethyl
esculetin (D), geniposide (G) and
rhein (R) were extracted from those
herb ingredients, respectively
Hepatic injury
syndrome (HI)
DGR combination could increase the plasma level, slow
elimination rate, exert a more robust therapeutic effect
than any one or two of the three individual compounds
by hitting multiple targets in a rat model of HI.
Zhang et al.,
2011
Checkerboard
dilution
method
In vitro Pseudolaric acid B (Herbal source
was not stated in the paper) and
fluconazole
Anti-fungal FICI showed a synergism of pseudolaric acid B and
fluconazole (0128 to 0.125µg/mL) against
azole-resistant clinical isolates of C. albicans, whereas
there was no such reaction with other Candida species.
Yan et al., 2012
In vitro Glabridin (from the root of
Glycyrrhiza glabra) and 17β-E2
Estrogenic
effect
When glabridin was treated together with 17β-E2 (1:1),
synergistic estrogenic effect was observed with a slight
decrease in cell proliferation as compared to treatment
by 17β-E2 alone.
Su Wei Poh
et al., 2015
0.67± 0.09). Similarly, Adams et al. investigated the interactions
among five popular herbs (Scutellaria baicalensis, Rabdosia
rubescens, Panax-pseudo ginseng, Dendranthema morifolium,
Glycyrrhiza uralensis and Serenoarepens) in 22Rv1 cell line using
the isobolographic analysis and revealed that the effects of the
four extract combination were significantly greater than that
of individual extracts alone and the two-by-two combinations
(Adams et al., 2006).
Identifying active Chemical Constituents Contributing
to Synergistic Interactions
In recent years, a new methodology that combining CI model
and fractionation technique was developed for identifying and
isolating synergistic interacted active constituents. For example,
in a study by Xu et al. (2014), synergistic anti-oxidant activities
of Astragalus membranaceus (AME) and Paeonia Lactiflora (PL)
combination were reported. In this study, AME and PL extracts
residues were combined and different fractions were obtained by
further sequential extraction with different solvents. Their anti-
oxidant effects were then tested using free radical scavenging
assay (DPPH), and total phenolic and flavonoid contents assays.
The fraction combination which showed synergistic effect by
CI model was selected for further fractionation. Eventually, the
optimized fraction producing the strongest synergistic effect was
subjected to HPLC-MS/MS analyses and seven components were
successfully identified which contributed to the anti-oxidant
activity of AME-PL combination including oxypaeoniflora,
catechin, calycosin-7-O-b-D-glucopyranoside, fomononetin-7-
O-b-Dglucopyranoside, 9,10-dimethoxy-pterocarpan-3-O-b-D-
glucopyranoside, quercetin, and 29-dihydroxy-39,49-dimethyl-
isoflavan-7-O-b-D-glucopyranoside (Xu et al., 2014). A similar
study was conducted by Wang et al. (2014) in a Radix Astragali
and Cimicifuga foetida combination (Wang et al., 2014). The
most potent fraction combinations were identified by comparing
different fractions from each herb and their combinations
using DPPH and ferric ion reducing antioxidant power
(FRAP) assays. Several bioactive components were identified
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FIGURE 3 | Histogram showing the general increase in synergy of Chinese herbal medicine related publications in the years 1999–2015 (up to June
only for 2015) from a bibliographic search in PubMed and Google Scholar database carried out in June 2015.
by HPLC-ESIMS/MS including calycosin, and formonoetin
from Radix Astragali, and ferulic acid and isoferulic acid
from Cimicifuga foetida (Wang et al., 2014). These studies
have clearly demonstrated a relatively efficient method to
isolate and identify active compounds from herbal combination,
providing an exemplar for mechanistic study of synergistic
effects of CHMs. However, it is worth pointing out that the
fractionation method employed in these two studies discarded
the “inactive” fractions and therefore, their possible interactions
with the active compounds were not tested/considered. Indeed,
it has been demonstrated that the antioxidant effects of
the active components isolated from Salvia plebeian R.
Br. were much weaker than that of the crude extracts,
indicating that the components “inactive” may play a role
in the pharmacological effects of the herbal combinations
(Gu and Weng, 2001).
Systematically Determine Synergistic Interactions
within Multi-Herb Formulations
“System to system (S2S)” or “systematic analysis” methods
integrating chemomic and systems biology have recently been
employed in the study of synergistic effects of complex herbal
formulations. This method analyses the multi-target actions
of mixed chemical constituents with a system of targeted
protein/receptors [see Section Systematic Analysis/System to
System (S2S)], thus it is more suitable for the complex nature
of TCM formula. For example, Liu Wei Di Huang Wan is a
classic TCM formula used to manage various complex diseases
such as hypertension and esophagus carcinoma. It consists of
6 herbal ingredients including Shu Di Huang (Rehmanniae
Radix Praeparata), Shan Zhu Yu (Corni Fructus), Mu Dan
Pi (Moutan Cortex), Shan Yao (Dioscoreae Rhizoma), Fu
Ling (Poria), and Ze Xie (Alismatis Rhizoma), each of them
were found to have multiple pharmacological effects. Liang
et al. (2014) attempted to evaluate the mechanisms underlying
the interactions of hundreds of chemical constituents in the
formula on their potential biological targets by utilizing a novel
network pharmacology approach. It was found that the key
synergistic interactions occur on multiple systems including
maintaining homeostasis in endocrine system, immune system
andmetabolism. However, the significance of this study is limited
due to the fact that not all potentially bioactive ingredients
from the formula were identified and that their pharmacological
properties were thoroughly defined. Nevertheless, the results
have demonstrated the holistic mode of action of a herb formula
targeting on a network based multi-systems, and highlighted
the difficulties associated with synergistic research in CHM
(Liang et al., 2014).
Li et al. (2012) attempted to illustrate the synergistic
mechanisms underpinning the “Jun-Chen-Zuo-Shi” theory of
CHM in a study of Danshen formula (CDF) using a systems-
pharmacological network model. CDF is commonly used for
CVDs consisting of Danshen (Radix Salviae Miltiorrhizae) as
the key (“Jun”) herb, Sanqi (Panax Notoginseng) as the adjuvant
(“Chen”) herb, and Borneol (Borneolum) as the courier (“Shi”)
herb. In this study major bioactive compounds that have high
oral bioavailability from each herb were screened and selected
through a robust in silico model OBioavail 1.1. Based on the
available pharmacological data of these candidate compounds,
their potential targets were searched through “PharmMapper
Server,” and those targets that were related to the pathological
processes of CVD were selected. Thus, the compound-target
network was constructed, and the interactions/relationship of
the compounds from each herb work on the same or different
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targets for CVD was investigated. The results demonstrated that
candidate compounds from Danshen tackled 39 out of total 41
validated CVD targets (except eNOS and ACE2), whereas that
from Sanqi interacted with 36 potential targets, 34 of which
overlapped with Danshen’s targets. Furthermore, the network
analysis showed that the compounds from Danshen targeted
the whole CVD systems, whereas that of Sanqi placed emphasis
on the modulation of vascular smooth muscle cells providing
evidence to support the former as the “Jun”/key herb and
the latter as the “Chen”/adjuvant herb in the formula (Li
et al., 2012). In a similar study, the underlying cardio- and
cerebrovascular protective mechanism of a complex formula
consisting of Radix Curcumae (Yujin), Fructus Gardeniae (Zhizi),
Moschus (Shexiang), and Borneolum (Bingpian) was assessed
by network reconstruction method through matching bioactive
components with good oral bioavailability with their potential
targets on cardio- and cerebrovascular system. The data showed
that 58 bioactive compounds identified from the herbs in the
formula were shown to interact with 32 potential targets relating
to cardiovascular and cerebrovascular diseases (CCVD). It was
suggested that Radix Curcumae was the key herb in this formula
as it contained the most candidate compounds that possessed
high degree distribution on CCVD related targets (8 targets)
followed by Fructus Gardeniae as the minister herb (5 targets),
Moschus (2 targets) as the adjuvant herb and Borneolum (0
targets) as the messenger herb (Tao et al., 2013).
In addition, systems biology can also be used to screen the
active components from the complex formula that act on the
major therapeutic targets. Shuanglong formula (SLF), consisting
of Panax ginseng and S. miltiorrhiza, is a popular Chinese
herbal formulation for the treatment of myocardial infarction
(MI) (Liang et al., 2012). Liang et al. (2012) employed a S2S
method using cell lines, isolated tissue and animal models to
optimize the phytochemical composition of SLF and revealed
that the cardiac protective effect of SLF is primarily through
synergistic interactions between ginsenosides and salvia acids
from Panax ginseng and S. miltiorrhiza, respectively (Liang
et al., 2012). Based on these results a new formulation, NFSL6
consisting total ginsenosides and total salvianolic acids at ratio of
7:3 was successfully developed using pharmacological screening.
Similarly, Wang et al. (2013) applied systematic analysis in
the study of Yinchenhao decoction (consisting Artemisia annua
L., Gardenia jasminoids Ellis, and Rheum Palmatum L.), a
classical formula used for treating hepatic injury syndrome.
Three major active components including 6,7-dimethylesculetin
(D), geniposide (G) and rhein (R) were found to be the
main contributors to the efficacy of the formula and the D-
G-R combination synergistically reduced histologic changes
and hepatocyte apoptosis, reversed the relevant metabolic
biomarkers, and modified 15 target protein expressions in the rat
hepatic injury model (Wang et al., 2013).
These studies have demonstrated that the “system to system”
or “systems-pharmacological network” models are applicable to
the study of synergistic effects in complex herbal formulations.
The results appear to support the rationality of “Jun-Chen-
Zuo-Shi” theory of complex Chinese herbal formulations
and promoted the understanding of the multi-components
interactions in these formulations. In addition, by exploring the
active fractions/components from a formula, it facilitates the
development of new formulations and/or new drug candidates.
However, these methods reply heavily on the availability of
the chemical and pharmacological data concerning the active
components in some well-studied herbs/herbal formulas and
therefore are not applicable to many herbs or herbal formulas in
which their active components unknown and molecular targets
unclear.
Synergistic Interactions between Chinese
Herbal Medicine and Pharmaceutical
Drugs
Due to the rapid expansion of the concurrent use of
pharmaceutical medicines and Chinse herbal medicine, research
into their interactions and the underlyingmechanisms is urgently
needed. Some of these interactions may be therapeutically
beneficial via synergism to enhance therapeutic effects or via
antagonism to reduce side effects. Most of the synergistic
studies available relate to anti-cancer therapies. For example,
anti-cancer properties of Polyphyllin I (PPI–active component
from Rhizoma of Paris polyphyllin) and Evodiamine (EVO–
active component from Evodia rutaecarpa) are well-documented
(Lee et al., 2005; Adams et al., 2007; Chan et al., 2009; Kong
et al., 2010), but their efficacy is generally weaker than that of
chemotherapeutic agents such as platinum (Pt), 5-Fluorouracil
(5-Fu), and irinotecan (CPT-11). However, when PPI or EVO
were combined with Pt or 5-Fu, it produced a significantly
stronger inhibition rate than Pt or 5-Fu alone on freshly-
removed gastric cancer tissues from patients. The CI values were
found to be <1 in all combinations at fraction affected (Fa)
= 80%, indicating a synergistic anti-cancer effect (Yue et al.,
2013).
Lin et al. (2014) demonstrated that the combination of
aqueous extract of the leaves and fruit of Camptotheca acuminate
(AE-CA) and cisplatin (platinum analogs) exerted synergistic
cytotoxicity effects in HEC-1A and HEC-1B human endometrial
carcinoma cells. This study also demonstrated that the cytotoxic
effect of the mixed AE-CA extracts was significantly stronger
than that of camptothecin (CPT), a chemotherapeutic drug
isolated from C. acuminate. However, the AE-CA extracts
produced similar effects on cell-cycle regulation and the
accumulation of cyclin-A2 and -B1 as CPT. Therefore, the
existence of synergistic effects among the individual components
in C. acuminate extracts remains unclear (Lin et al., 2014).
Similarly, the synergistic effects of bioactive dichloromethane
(DCM) subfraction of Strobilanthes crispus leaves (SCS) and
tamoxifen (antiestrogen drug) were investigated using estrogen
receptor-responsive and non-responsive breast cancer cells
(MCF-7 and MDA-MB-231 cell lines). SCS extracts alone
induced around 50% cell death after 24 h treatment. When
combined with low doses of tamoxifen (which did exert any
significant cytotoxic effect on its own), SCS extracts produced
80% cell death after 24 h treatment, which was proved to be
a synergistic effect based on the method of CI using Calcusyn
software (Yaacob et al., 2014).
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A study by Seo et al. (2014) has shown that a mixture of
curcumin, a main bioactive component of Curcuma longa and
NVP-BEZ 235 (a potent dual inhibitor of PI3K and mTOR)
can synergistically induce apoptosis in human renal carcinoma
caki cells (Seo et al., 2014). The mixture of 2 µM NVP-BEZ235
and 30 µM curcumin significantly provoked cell shrinkage,
membrane blebbing, chromatin damage in the nuclei and DNA
fragmentation; none of these effects were as significant when
curcumin and NVP-BEZ235 were used alone. Isobologram
analyses demonstrated that there were synergistic activities
between curcumin and NVP-BEZ 235.
Synergistic Interactions between Chinese
Herbal Medicine and Antibiotics in
Microbiology Studies
Synergistic effects between antibiotics and herbal medicine have
also been extensively studied. Agar diffusion assay is often
used for screening the anti-bacterial activity of individual agent,
and used as qualitative guide for positive/negative interaction
guide for agents’ mixture. For example, four active constituents
(pseudolaric acid B, gentiopicrin, rhein and alion) extracted
from CHMs (herbal source was not stated in the paper) were
tested on agar diffusion assay, and only pseudolaric acid B
showed significant fungicidal activity with growth inhibition
zones ranging from 8 to 25mm against C. albicans, C. glabrata,
C. krusei, C. tropicalis, C. dubliniensis and C. parapsilosis.
Furthermore, a positive interaction was observed between
pseudolaric acid B and fluconazole in the agar diffusion assay
on the same disc, where there was no microcolony growth in
the cross-sectional area of pseudolaric acid B and fluconazole
observed (Jiang et al., 2010). In addition, checkerboard array
and time-kill assay are commonly used methods to quantitively
determine the synergism/addition/antagonism interactions. Jang
et al. (2014) explored the synergistic antibacterial activities of
baicalein, a flavonoid originally isolated from the root of S.
baicalensis Georgi, with ampicillin and/or gentamicin against a
range of oral bacteria strains. Their results showed that both
baicalein-ampicillin and baicalein-gentamicin combinations
demonstrated synergistic bactericidal effects evidenced by
FICI ≤ 0.5 determined by checkerboard array (Jang et al.,
2014). In addition, time-kill array results confirmed the
positive interaction between baicalen–ampicillin and baicalen–
gentamicin, respectively, which showed substantially stronger
bactericidal effect in combination compared with individual
effect from 0 to 24 h (Jang et al., 2014). Similarly, Hwang et al.
(2013) also utilized checker-board array to analyse the synergistic
effect between amentoflavone (biflavonoid class of flavonoids,
isolated from Selaginella tamariscina) and antibiotics such
as ampicillin, cefotaxime and chloramphenicol. Their results
showed that amentoflavone had a considerable antibacterial effect
and exerted synergistic interactions with antibiotics against all
bacterial strains tested (FICI ≤ 0.5) except for Streptococcus
mutans. This synergistic effect was suggested to be largely
mediated by the formation of hydroxyl radical by nicotinamide
adenine dinucleotide phosphate (NADH) depletion (Hwang
et al., 2013).
CONCLUSION
In this review, we have clarified the definition of synergy
from two angles pharmacodynamics (enhanced therapeutic
actions on the same target) and pharmacokinetics (no direct
interaction but with multi-target behavior), as well as elucidated
the common misconceptions of synergy. It is critical to
distinguish between synergistic effects and simple additive
effects of individual herbs or active ingredients in a complex
herbal formulation. Several rigorous analytical methods such
as isobolographic analysis, combination index (CI), and
systems biology have been developed for the quantitative
evaluations of synergistic effects. These methods have greatly
facilitated the development and standardization of combination
therapies (e.g., chemotherapy treatment) in conventional
western medicine. However unlike western medicine where
the chemical and pharmacological properties of individual
drugs are clearly defined, herbal medicine often contains
numerous active ingredients, which can all contribute to their
synergy effects. This poses a huge challenge in the study of
synergistic effects of herbal medicine and a different research
approach is needed to accurately evaluate and quantify these
effects.
We have also summarized current available methods for
the study of synergistic effects of CHM. These methods have
been successfully used to determine the nature (i.e., synergistic,
additive, or antagonistic) of the interactions within single herbs,
multiple herbal formulations or between pharmaceutical drugs
and herbal medicine. Each of these methods has strengths
and weaknesses and therefore careful consideration should be
given when designing a synergistic study of herbal medicine.
For example, the CI and isobologram models are relatively
fast and simple and are ideal for studying the interactions
of a small number of active components or herbal extracts
in which their chemical and pharmacological properties are
well-defined. However, the CI or isobologram methods are
designed for mono-target therapies, and it is of limited use
in demonstrating synergistic effects in complex combined
therapies especially those in CHM. S2S mode/systems biology
methods approach the issues from a systematic perspective,
which is consistent with the holistic approach of Chinese
medicine. This network system may be more suited for the
study of synergistic mechanisms underlying complex herbal
formulations. However, these methods rely on the availability
of large amount of chemical and pharmacological data, which
are absent at the moment for most of the herbs and
herbal formulations. More research into the chemical and
molecular/pharmacological bases of herbal medicine and their
bioactive components is needed before these analyses can be
applied more broadly.
In summary, synergy research on CHM is still at its
infancy. The currently available methods have various significant
limitations on the synergy studies of CHM; more methodological
development is urgently needed in the future. Despite synergistic
effects demonstrated in numerous pharmacological studies,
these findings do not always represent the clinical therapeutic
superiority. Therefore, the clinical benefits of multi-component
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combinations must be subsequently confirmed in rigorous
clinical trials.
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